[1]樊德慧 金娟 韩宇博 田苗 刘莉.利钠肽与代谢综合征的研究进展[J].心血管病学进展,2020,(10):1074.[doi:10.16806/j.cnki.issn.1004-3934.20.10.018]
　FAN Dehui,JIN Juan,HAN Yubo,et al.Research Progress of Natriuretic Peptide and Metabolic Syndrome[J].Advances in Cardiovascular Diseases,2020,(10):1074.[doi:10.16806/j.cnki.issn.1004-3934.20.10.018]
点击复制

利钠肽与代谢综合征的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2020年10期
页码:
1074
栏目:
综述
出版日期:
2020-10-25

文章信息/Info

Title:
Research Progress of Natriuretic Peptide and Metabolic Syndrome
作者:
樊德慧1 金娟2 韩宇博2 田苗1 刘莉2
(1.黑龙江中医药大学,黑龙江 哈尔滨 150040;2.黑龙江中药大学附属第一医院心血管一科,黑龙江 哈尔滨 150040)
Author(s):
FAN Dehui1; JIN Juan2; HAN Yubo2; TIAN Miao2; LIU Li2
(1.Heilongjiang University of Chinese Medicine,Harbin 150040,Heilongjiang,China; 2.Department of Cardiology,The First Affiliated Hospital of Heilongjiang University of Chinese Medicine,Harbin 150040,Heilongjiang,China)
关键词:
利钠肽; 代谢综合征; 肥胖; 胰岛素抵抗; 心血管危险因素
Keywords:
Natriuretic peptide;  Metabolic syndrome; Obesity; Insulin resistance;  Cardiovascular disease
DOI:
10.16806/j.cnki.issn.1004-3934.20.10.018
摘要:
代谢综合征（MS）是一组以肥胖，血糖、血压和血脂异常为主要表现的全身代谢紊乱性综合征，其发病率逐年增高，已成为全球公共卫生问题，MS各组成要素均可增加心血管疾病及2型糖尿病的发病风险及死亡率，严重威胁着人类的健康，因此治疗MS已成为目前亟待解决的问题。利钠肽是由心脏、脑及血管内皮等分泌的肽类物质，主要分为心房利钠肽、脑钠肽及C型利钠肽，具有利钠、利尿和舒张血管等作用。最新发现利钠肽还具有调节糖脂代谢的作用，在防治肥胖及MS中起到关键性的作用。现旨在通过探讨利钠肽与MS各组成要素的关系，为MS的治疗提供新思路。
Abstract:
Metabolic syndrome(MS) is a group of systemic metabolic disorder syndrome with obesity,abnormal blood glucose,abnormal blood pressure and abnormal blood lipid. Its incidence is increasing year by year,which has become a global public health problem. All elements of MS can lead to an increase in the risk and mortality of cardiovascular disease and type 2 diabetes,which seriously threatens human health. Therefore,the treatment of MS has become an urgent problem. Natriuretic peptide is a kind of peptide secreted by the heart,brain and vascular endothelium. It is mainly divided into atrial natriuretic peptide,brain natriuretic peptide and C-type natriuretic peptide,which have diuretic,natriuretic,and vasodilatory properties. Recently,it was found that natriuretic peptide can also regulate the metabolism of glucose and lipid,and play a key role in the prevention and treatment of obesity and MS. The purpose of this paper is to provide new ideas for the treatment of MS by exploring the effect of natriuretic peptide on the components of MS.

参考文献/References:

[1]. Saklayen MG. The global epidemic of the metabolic syndrome[J]. Curr Hypertens Rep, 2018,20(2):12.
[2].[] Verboven K,Hansen D,Jocken JWE,et al. Natriuretic peptides in the control of lipid metabolism and insulin sensitivity[J]. Obes Rev,2017,18(11):1243-1259.
[3].[] Dessì-Fulgheri P,Sarzani R,Rappelli A. Role of the natriuretic peptide system in lipogenesis/lipolysis[J]. Nutr Metab Cardiovasc Dis,2003,13(4):244-249.
[4].[] Ahued-Ortega JA,León-García PE,Hernández-Pérez E. Correlation of plasma B-type natriuretic peptide levels with metabolic risk markers[J]. Med Clin (Barc),2018,151(12):481-486.
[5].[] Fu S,Ping P,Wang F,et al. Synthesis,secretion,function,metabolism and application of natriuretic peptides in heart failure[J]. J Biol Eng,2018,12(1):2.
[6].[] Lee CYW,Burnett JC. Natriuretic peptides and therapeutic applications[J]. Heart Fail Rev,2007,12 (2):131-142.
[7].[] Coué M,Moro C. Natriuretic peptide control of energy balance and glucose homeostasis[J]. Biochimie, 2016,124:84-91.
[8].[] Matsuo A,Nagai-Okatani C,Nishigori M,et al. Natriuretic peptides in human heart:Novel insight into their molecular forms, functions,and diagnostic use[J]. Peptides,2019,111:3-17.
[9].[] Wang TJ,Larson MG,Levy D,et al. Impact of obesity on plasma natriuretic peptide levels[J]. Circulation, 2004,109(5):594-600.
[10].[] Gentili A,Frangione MR,Albini E,et al. Modulation of natriuretic peptide receptors in human adipose tissue:molecular mechanisms behind the“natriuretic handicap”in morbidly obese patients[J]. Transl Res,2017,186:52-61.
[11].[] Suthahar N,Meijers WC,Ho JE,et al. Sex-specific associations of obesity and N-terminal pro-B-type natriuretic peptide levels in the general population[J]. Eur J Heart Fail,2018,20(8):1205-1214.
[12].[] Del Ry S,Cabiati M,Bianchi V,et al. C-type natriuretic peptide is closely associated to obesity in Caucasian adolescents[J]. Clin Chim Acta,2016,460:172-177.
[13].[] Bae CR,Hino J,Hosoda H,et al. Adipocyte-specific expression of C-type natriuretic peptide suppresses lipid metabolism and adipocyte hypertrophy in adipose tissues in mice fed high-fat diet[J]. Sci Rep, 2018,8(1):2093.
[14].[] Coué M, Barquissau V, Morigny P,et al. Natriuretic peptides promote glucose uptake in a cGMP-dependent manner in human adipocytes[J]. Sci Rep,2018,8(1):1097.
[15].[] Bordicchia M,Ceresiani M,Pavani M,et al. Insulin/glucose induces natriuretic peptide clearance receptor in human adipocytes: a metabolic link with the cardiac natriuretic pathway[J]. Am J Physiol Regul Integr Comp Physiol,2016,311(1):R104-R114.
[16].[] Kim F,Biggs ML,Kizer JR,et al. Brain natriuretic peptide and insulin resistance in older adults[J]. Diabet Med,2017,34(2):235-238.
[17].[] Coué M,Moro C. Natriuretic peptide control of energy balance and glucose homeostasis[J]. Biochimie, 2016,124:84-91.
[18].[] Wu W,Shi F,Liu D,et al. Enhancing natriuretic peptide signaling in adipose tissue, but not in muscle, protects against diet-induced obesity and insulin resistance[J]. Sci Signal,2017,10(489):E6870.
[19].[] Gruden G,Landi A, Bruno G. Natriuretic peptides,heart, and adipose tissue:new findings and future developments for diabetes research[J]. Diabetes Care,2014,37(11):2899-2908.
[20].[] Benomar K,Espiard S,Loyer C,et al. Atrial natriuretic hormones and metabolic syndrome: recent advances[J]. Presse Med,2018,47(2):116-124.
[21].[] Bae CR,Hino J,Hosoda H,et al. Overexpression of C-type natriuretic peptide in endothelial cells protects against insulin resistance and inflammation during diet-induced obesity[J]. Sci Rep,2017,7(1):9807.
[22].[]上官娇玲,凌智瑜. 心血管疾病风险指标新进展[J]. 心血管病学进展,2019,40(2):59-63.
[23].[] Zhang T,Chen J,Tang X,et al. Interaction between adipocytes and high-density lipoprotein:new insights into the mechanism of obesity-induced dyslipidemia and atherosclerosis[J]. Lipids Health Dis,2019,18(1):223.
[24].[] Masuch A,Pietzner M,Bahls M,et al. Metabolomic profiling implicates adiponectin as mediator of a favorable lipoprotein profile associated with NT-proBNP[J]. Cardiovasc Diabetol,2018,17(1):120.
[25].[] Wang JH,Lee CJ,Hsieh JC,et al. Serum atrial natriuretic peptide level inversely associates with metabolic syndrome in older adults[J]. Geriatr Gerontol Int,2014,14(3):640-646.
[26].[] He WT,Mori M,Yu XF,et al. Higher BNP levels within physiological range correlate with beneficial nonfasting lipid profiles in the elderly: a cross-sectional study[J]. Lipids Health Dis,2016,15:3.
[27].[] Spannella F,Giulietti F,Cocci G,et al. N-terminal pro B-Type natriuretic peptide is inversely correlated with low density lipoprotein cholesterol in the very elderly[J]. Nutr Metab Cardiovasc Dis,2018,28(6): 629-635.
[28].[] Goharian TS,Goetze JP,Faber J,et al. Associations of proatrial natriuretic peptide with components of the metabolic syndrome in adolescents and young adults from the general population[J]. Am J Hypertens,2017,30(6):561-568.
[29].[] Rubattu S,Sciarretta S,Ciavarella GM,et al. Reduced levels of N-terminal-proatrial natriuretic peptide in hypertensive patients with metabolic syndrome and their relationship with left ventricular mass[J]. J Hypertens,2007,25(4):833-839.
[30].[] Asferg CL,Andersen UB,Linneberg A,et al. Serum proatrial natriuretic peptide does not increase with higher systolic blood pressure in obese men[J]. Heart,2017,103(2):154-158.
[31].[] Davogustto G,Wang TJ,Gupta DK. Untangling essential hypertension:the potential roles of aldosterone and atrial natriuretic peptide[J]. Mayo Clin Proc,2018,93(8):965-967.
[32].[] Cannone V, Cabassi A, Volpi R,et al. Atrial natriuretic peptide:a molecular target of novel therapeutic approaches to cardio-metabolic disease[J]. Int J Mol Sci,2019,20(13):3265.
[33].[] Vandenwijngaert S,Ledsky CD,Lahrouchi N,et al. Blood pressure-associated genetic variants in the natriuretic peptide receptor 1 gene modulate guanylate cyclase activity.[J]. Circ Genom Precis Med,2019, 12(8):e002472.
[34].[] Bie P. Natriuretic peptides and normal body fluid regulation[J]. Compr Physiol,2018,8(3): 1211-1249.
[35].[] Jordan J,Stinkens R,Jax T,et al. Improved Insulin sensitivity with angiotensin receptor neprilysin Inhibition in individuals with obesity and hypertension[J]. Clin Pharmacol Ther,2017,101(2): 254-263.

相似文献/References:

[1]王海星,尹德春,曲秀芬.病态窦房结综合征的心房纤维化血清学指标研究进展[J].心血管病学进展,2020,(3):310.[doi:10.16806/j.cnki. issn.1004-3934.2020.03.023]
　WANG Haixing,YIN Dechun,QU Xiufen.Serological Indicators of Atrial Fibrosis for Sick Sinus Syndrome[J].Advances in Cardiovascular Diseases,2020,(10):310.[doi:10.16806/j.cnki. issn.1004-3934.2020.03.023]
[2]任蕾 夏芳芳 戴红艳.血管生成素样蛋白6在心血管病方面的研究进展[J].心血管病学进展,2020,(4):388.[doi:10.16806/j.cnki.issn.1004-3934.20.04.015]
　REN Lei,XIA FangFang,DAI HongYan.Relationship Between ANGPTL6 and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(10):388.[doi:10.16806/j.cnki.issn.1004-3934.20.04.015]
[3]薛建强 刘玉萍 倪国华 孙颖 孙平.60岁以上人群身体测量指标对代谢综合征的预测价值[J].心血管病学进展,2022,(10):947.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.019]
　XUE Jianqiang,LIU Yuping,NI Guohua,et al.Predictive Value of Body Measurements for Metabolic Syndrome in People Over 60 Years of Age[J].Advances in Cardiovascular Diseases,2022,(10):947.[doi:10.16806/j.cnki.issn.1004-3934.2022.10.019]

更新日期/Last Update: 2020-12-21